CI 1044

Drug Profile

CI 1044

Alternative Names: PD 189659

Latest Information Update: 16 Feb 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Antiasthmatics; Azepines; Nicotinic-acids; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 16 Feb 2006 No development reported - Preclinical for Chronic obstructive pulmonary disease in France (PO)
  • 10 Feb 2005 No development reported - Phase-I for Asthma in France (PO)
  • 10 Feb 2005 No development reported - Phase-I for Asthma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top